Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CCR1 | P32246 | 19/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066761 | 0.90 | CCR1 (0.55) | SMN1; SMN2CCR1CYP2C19KCNH2 | |
| SCHEMBL3067164 | 0.90 | CCR1 (0.55) | SMN1; SMN2CCR1CYP2C19KCNH2 | |
| SCHEMBL3068586 | 0.83 | CCR1 (0.57) | SMN1; SMN2CCR1CYP2C19KCNH2 | |
| SCHEMBL3073115 | 0.81 | ALDH1A1 (0.60) | CCR1 | |
| SCHEMBL3464688 | 0.77 | CCR1 (0.64) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3468992 | 0.76 | CCR1 (0.72) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3465626 | 0.76 | CCR1 (0.66) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3465393 | 0.76 | CCR1 (0.59) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3077032 | 0.76 | CCR1 (0.61) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3063748 | 0.76 | CCR1 (0.63) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1931348-A4 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1931348-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | SMN1; SMN2 1719/4885CCR1 1/4885CYP2C19 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.